Diagnostics News and Research

RSS

Primeradx raises funds for commercialization of their technology

PrimeraDx, Inc., a privately held molecular diagnostics company, announced today that it has closed on its $20 million Series C financing. The financing was led by CHL Medical Partners and also included significant participation by many of the Company’s existing investors; Abingworth, InterWest Partners, Malaysian Technology Development Corporation, MPM Capital, Burrill & Company and the Invus Group.

21 Sep 2009

Sleep Diagnostics assests sold to Embla Systems

Covidien, a leading global provider of healthcare products, today announced that it had completed the previously announced sale of its Sleep Diagnostics assets to Embla Systems. Financial terms of the transaction were not disclosed.

21 Sep 2009

NIAID awards Antigen Discovery a Phase II STTR grant for Chlamydia vaccine development

Antigen Discovery, Inc. ("ADi", formerly ImmPORT Therapeutics, Inc.), a leading biotech company in high throughput antigen and biomarker discovery, announced today that the Company was awarded a Phase II STTR from the National Institute of Allergy and Infectious Diseases (NIAID) under the American Recovery and Reinvestment Act (ARRA) of 2009.

21 Sep 2009

Hypertension Diagnostics' revenue decreases by 9.2% for the fiscal year 2009

Hypertension Diagnostics, Inc. (OTCBB: HDII), today announced audited financial results for the fiscal year ended June 30, 2009.

21 Sep 2009

Simple eye movement exam can differentiate between a stroke and less serious conditions

...

21 Sep 2009

Health Discovery Corporation appoints new COO

Health Discovery Corporation, a personalized medicine company specializing in molecular diagnostics including gene-based testing, as well as computer assisted diagnostics in digital pathology and radiology, announced that former Deputy FDA Commissioner John A. Norris has been appointed as Chief Operating Officer (COO) of the Company.

19 Sep 2009

Scientific discoveries must be translated into practical applications to improve patients' health

Experts gathered on Capitol Hill today to address the impact of policies related to translational research and U.S. medical innovation. The briefing, titled Translational Research: From Bench to Bedside, was sponsored by the Council for American Medical Innovation as the second in a three-part series, Recovery Through Discovery, which examines medical innovation as a driver of U.S. economic recovery and enhanced global leadership in science.

18 Sep 2009

Research to identify breast cancer disparities

In an effort to continue to deliver on its vision of a world without breast cancer, Susan G. Komen for the Cure,((R) )San Diego conducted an in-depth, county-wide research and community needs assessment to identify disparities in breast cancer across populations.

18 Sep 2009

Phase I trial of NPC-1C to commence

Neogenix Oncology, Inc. (Neogenix) announced today that NPC-1C, the company’s first IND (Investigational New Drug Application) was granted permission by the Food and Drug Administration (FDA) for the company to begin a Phase I trial.

18 Sep 2009

UCSF chooses Think First to support revenue cycle performance

Think First, a premier provider of revenue cycle services, has been chosen by the University of California San Francisco (UCSF) Medical Group to support their efforts to improve revenue cycle performance.

17 Sep 2009

Biomagnetics and U.S. Government laboratory continue contract negotiations

Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, today announced the Company is in continuing contract negotiations to acquire the rights to Integrated Optical Biosensor System (IBOS) technology developed by one of the U.S. Government’s top national security research institutions.

17 Sep 2009

Three senior analysts appointed by Jefferies for healthcare equity research

Jefferies today announced the expansion of its Healthcare Equity Research effort with the hiring of three senior analysts. Corey Davis, PhD has joined as a Managing Director covering Specialty Pharmaceuticals, Thomas Wei will join next month as a Managing Director covering Biotechnology, and Jon Davis Wood will join later this month as a Senior Vice President covering Life Sciences Tools. All three professionals will be based in New York.

17 Sep 2009

Seegene awarded patent in the U.S. and Europe for Annealing Control Primer

Seegene, Inc., a leader in multi-pathogen diagnostic testing, today announced that it has been awarded patent in the U.S. and Europe for Annealing Control Primer (ACP), a new technology for amplifying a specific region of a gene with much higher specificity and reproducibility than conventional approaches.

17 Sep 2009

Cancer Program established to treat young cancer patients

A new partnership of Providence Health & Services, Childrens Hospital Los Angeles and the Childrens Hospital Los Angeles Medical Group has been developed to treat young adults with cancer, providing diagnostics and treatment for a group that nationwide falls in a gap between adult and pediatric health care.

16 Sep 2009

Four H1N1 vaccines approved by FDA

The U.S. Food and Drug Administration announced today that it has approved four vaccines against the 2009 H1N1 influenza virus. The vaccines will be distributed nationally after the initial lots become available, which is expected within the next four weeks.

16 Sep 2009

FDA clears Olerup SSP’s Taq-polymerase-free HLA typing kit for sale in the U.S.

Olerup SSP, a wholly owned subsidiary of LinkMed (STO:LMED), has had its Taq-polymerase-free HLA typing kit registered and cleared by the FDA. This means that Olerup SSP’s entire product range for HLA typing, with or without Taq polymerase, can now be marketed and sold to a greater number of healthcare centers in North America.

15 Sep 2009

Council briefing series to examine role of public policy in promoting medical innovation

The Council for American Medical Innovation will host a breakfast briefing on Capitol Hill titled "Translational Research - From Bench to Bedside." Health policy experts will explore important changes needed to improve the process of development and approval for safe and effective drugs, biologics, medical devices and diagnostics.

15 Sep 2009

Biocryst signs agreement with three partners to represent its anti-viral peramivir outside U.S.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has signed binding letters of intent with three partners who will exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities, as well as for marketing and distribution of peramivir for seasonal influenza upon local regulatory approval, within their territories outside the U.S.

15 Sep 2009

RAPS honors award recipients for contributions to healthcare product regulatory profession

The Regulatory Affairs Professionals Society (RAPS) today honored the recipients of its prestigious awards for outstanding contributions to the healthcare product regulatory profession. RAPS' Leonard Stauffer Award for mentoring and furthering regulatory professional education was given to independent consultant Nanci Dexter.

15 Sep 2009

Targeted Molecular Diagnostics to offer digital pathology services in Beijing

Targeted Molecular Diagnostics (TMD), a Quintiles Central Laboratory, announced today the availability of digital pathology services in Beijing, China. The services add to Quintiles offerings used in the development of therapies to treat the world’s most pressing health issues, including cancer.

15 Sep 2009